Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

NCT07130903 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: Fruquintinib
DEVICE: TheraBionic P1

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]